Giuseppe
Emeritus
Vaccine. 2008 Oct 15. [Epub ahead of print]
Seasonal influenza vaccine delivered by intradermal microinjection: A randomised controlled safety and immunogenicity trial in adults.
Leroux-Roels I, Vets E, Freese R, Seiberling M, Weber F, Salamand C, Leroux-Roels G. - Center for Vaccinology, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium.
Influenza vaccines remain largely underused.
A promising alternative to current intramuscular vaccines is a trivalent inactivated influenza vaccine (TIV) delivered using a microinjection system to offer a less invasive and possibly more acceptable vaccination.
A phase II, multicentre, randomised open-label study in 978 healthy adults (18-57 years) evaluated the immunogenicity and safety of intradermal TIV.
Subjects received a 0.1ml injection of intradermal TIV, containing 9mug of haemagglutinin (HA) per strain (n=588) or a conventional 0.5ml intramuscular vaccine (15mug of HA/strain; n=390). Intradermal TIV induced non-inferior humoral immune responses against all three strains and superior responses against both A strains (H1N1, H3N2) compared with the control. Both vaccines were well tolerated.
PMID: 18930093 [PubMed - as supplied by publisher
-
-----
Seasonal influenza vaccine delivered by intradermal microinjection: A randomised controlled safety and immunogenicity trial in adults.
Leroux-Roels I, Vets E, Freese R, Seiberling M, Weber F, Salamand C, Leroux-Roels G. - Center for Vaccinology, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium.
Influenza vaccines remain largely underused.
A promising alternative to current intramuscular vaccines is a trivalent inactivated influenza vaccine (TIV) delivered using a microinjection system to offer a less invasive and possibly more acceptable vaccination.
A phase II, multicentre, randomised open-label study in 978 healthy adults (18-57 years) evaluated the immunogenicity and safety of intradermal TIV.
Subjects received a 0.1ml injection of intradermal TIV, containing 9mug of haemagglutinin (HA) per strain (n=588) or a conventional 0.5ml intramuscular vaccine (15mug of HA/strain; n=390). Intradermal TIV induced non-inferior humoral immune responses against all three strains and superior responses against both A strains (H1N1, H3N2) compared with the control. Both vaccines were well tolerated.
PMID: 18930093 [PubMed - as supplied by publisher
-
-----